FULCRUM THERAPEUTICS, INC. Restructuring Charges
FULCRUM THERAPEUTICS, INC. (FULC) reported Restructuring Charges of $4.30 thousand for the 3-month period ending 2026-06-30, per its S-4 filed 2026-09-02.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-09-02
- FULCRUM THERAPEUTICS, INC. restructuring charges for the quarter ending 2026-06-30 was $4.30K.
- FULCRUM THERAPEUTICS, INC. restructuring charges for the quarter ending 2025-12-31 was $400.00K, a 76.47% decline year-over-year.
- FULCRUM THERAPEUTICS, INC. restructuring charges for the quarter ending 2025-09-30 was $0.00.
- FULCRUM THERAPEUTICS, INC. restructuring charges for the quarter ending 2025-06-30 was $0.00.
- FULCRUM THERAPEUTICS, INC. restructuring charges for fiscal 2022 was $400.00K.
| Period end | Restructuring Charges 3 month | Restructuring Charges 3 month as first filed | Restructuring Charges 6 month | Restructuring Charges 6 month as first filed | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4.30K S-4 · filed 2026-09-02 | $4.30M 10-Q · filed 2026-07-30 | $4.30K S-4 · filed 2026-09-02 | $4.30M 10-Q · filed 2026-07-30 | ||
| 2025-12-31 | $400.00K derived: S-4 12 month − 10-Q 9 month · filed 2026-09-02 | $400.00K derived: sum of 2 quarters · filed 2026-09-02 | $400.00K derived: sum of 3 quarters · filed 2026-09-02 | $400.00K S-4 · filed 2026-09-02 | ||
| 2025-09-30 | $0.00 10-Q · filed 2025-10-29 | $0.00 derived: sum of 2 quarters · filed 2025-10-29 | $0.00 10-Q · filed 2025-10-29 | $1.70M derived: sum of 4 quarters · filed 2026-09-02 | ||
| 2025-06-30 | $0.00 10-Q · filed 2025-07-29 | $0.00 10-Q · filed 2025-07-29 | $1.70M derived: sum of 3 quarters · filed 2026-09-02 | $1.70M derived: sum of 4 quarters · filed 2026-09-02 | ||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-01 | $1.70M derived: sum of 2 quarters · filed 2026-09-02 | $1.70M derived: sum of 3 quarters · filed 2026-09-02 | |||
| 2024-12-31 | $1.70M derived: S-4 12 month − 10-Q 9 month · filed 2026-09-02 | $1.70M derived: sum of 2 quarters · filed 2026-09-02 | $1.70M S-4 · filed 2026-09-02 | |||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | ||||
| 2022-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-26 | $400.00K derived: sum of 2 quarters · filed 2023-06-26 | $400.00K 10-K/A · filed 2023-06-26 | |||
| 2022-09-30 | $400.00K 10-Q · filed 2022-11-08 | $400.00K 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |